67Cu-SARTATE (67Cu-SAR-[Tyr3]-Octreotate) is a therapeutic radiolabeled somatostatin analogue of 64Cu-SARTATE and the first Copper-67 labeled drug that entered clinical trials.

67Cu-SARTATE is targeting first meningioma but in reality, is a competitor to existing somatostatin analogue labeled tracers developed in the NET indication. 67Cu-SARTATE entered phase I/II trials in meningioma patients Australia in May 2019 . The study (5 patients) was completed in September 2019. Another clinical Phase I/II trial in pediatric patients with high risk neuroblastoma was initiated in July 2019, but the recruitment started only in July 2020 with an expected completion in September 2022.

Target/Mechanism: somatostatin receptors

Leading Emitter: beta electrons (β)